Buradasınız

Anasayfa » Content

FİBRİNOJEN VE KORONER ARTER HASTALIĞI

Fibrinogen and coronary artery disease

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective. It has previously been shown that fibrinogen is involved in the pathogenesis of atherosclerosis and coronary artery disease. However, only a few studies have shown the correlation between the fibrinogen level and the extent of coronary artery disease and the presence of total luminal occlusion. The purpose of this study was to verify the existence of a correlation between fibrinogen and the presence of total luminal occlusion and the extent of coronary artery d sease n our study populat on. Methods and Results. The patients were characterized with regard to presence or absence of total lum nal occlus on and the extent of coronary artery d sease (s ngle, double and triple vessels). The study population included 360 patients with coronary artery disease. 129 patients had total luminal occlusion. The remaining patients did not have total luminal occlusion. Additionally single vessel patients had 165 and double vessel pat ents had 135 and tr ple vessel pat ents had 60. The levels of plasma f br nogen n the patients with total luminal occlusion were significantly higher than the patients without total luminal occlusion (4.76±1.36 g/l vs 4.21±1.04g/l, p?0.001). Also, fibrinogen ncreased stead ly as the number of nvolved vessels r sed (respect vely, 4.52±1.18 g/l, 4.63±1.33g/l and 4.70±1.15g/l, p?0.05). Conclusion. These data suggest that high values of fibrinogen may indicate the presence of total lum nal occlus on and mult ple vessel d sease.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç. Fibrinojenin aterosklerozis ve koroner arter hastalığının patoge-nezinde yer aldığı daha önceden gösterilmiştir. Fakat fibrinojen düzeyinin koroner arter hastalığının yaygınlığı ve tam tıkanıklığın varlığı ile ilişkisi sadece birkaç çalışmada gösterilmiştir. Bu çalışmanın amacı çalışma po-pulasyonumuzda koroner arter hastalığının yaygınlığı ve tam tıkanıklığın varlığı ile fibrinojen arasında bir ilişkinin varlığını belirlemek idi. Metod ve Bulgular. Hastalar tam tıkanıklığın varlığına veya yokluğuna ve koroner arter hastalığının yaygınlığına (tek damar, iki damar ve üç damar) göre sınıflandırıldı. Çalışma grubu koroner arter hastalığı olan 360 hastayı içeriyordu. Bu hastaların 129'unda tam tıkanıklık varken geri kalan hastalarda tam tıkanıklık yoktu. Ayrıca tek damar hastalığı 165, iki damar hastalığı 135, üç damar hastalığı 60 hastada mevcuttu. Tam tıkanıklığı olan hastaların plazma f br nojen düzeyler tam tıkanıklığı olmayan hastalardan daha yüksekt (4.76±1.36 g/Ye karşın 4.21±1.04 g/l, p?0.001). Aynı zamanda hasta damar sayısı arttıkça fibrinojen kararlı bir şekilde artıyordu (sırasıyla, 4.52±1.18 g/l, 4.63±1.33 g/l ve 4.70±1.15 g/l, p?0.05). Sonuç. Bu sonuçlar yüksek fibrinojen düzeylerinin tam tıkanıklığın ve çok damar hastalığının varlığını göstereb leceğ ne şaret etmekted r.
FULL TEXT (PDF): 
PDF icon arastrmx_5674_6_pp_136-139.pdf
  • 2
136-139
  • Turkish

REFERENCES

References: 

1. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease; principal results of the Northwick Part Heart Study, Lancet 1986; 336; 533-7.
2. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent cluadication, coronary heart disease, and family history: the Scottish Heart Study. Br Heart J 1993; 69: 338-42.
3. ECAT Angina Pectoris Study Group. ECAT angina pectories study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factor in 3000 patients with angina pectories undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
4. Wilhelmsen L, Svardsudd K, Korsan-Bergtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984 ; 311: 501-5.
5. Kannel WB, Wolf PA, Castelli WP. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258-1183-6.
6. Stone MC, Thorpe JM. Plasma fibrinogen -a major coronary risk factor. J R Coll Gen pract 1985; 35; 565-9.
7. Lowe GDD, Drummond MM, Larimer AR, Hutton I, Forbes CD, Prentice, CR. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980; 1: 673-4.
8. Kruskal JB, Cammer ford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen -related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 317: 1361-5.
9. Baller D, Miche E, Gleichmann U. Hyperfibrinogenemia and relative leucocytosis in unstable angina and in patients with angiographic signs of intracoronary thrombosis. Blood Coag Fibrinol 1994 ; 5 (Suppl 2) (Abstr 0-25).
10. Haverkate F. Thrombosis and disabilities. In: Baya C, ed. Advances in medical biology, IOS Press, 1994: 81-103.
11. Clauss A Gerinnung sphysiologische Schnellmethode Zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
12. Siedel J. Hagele EO, Zigenehorn J, et al. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chan 1983; 29: 1075-80.
13. Mc Gowan WM, Artiss JA, Strendber DR, et al. A peroxidase coupled method for the colorimetric determination of the triglycerdies. Clin Chem 1983; 29: 538-42.
14. Kopes-Virella MF, Stone P, Ellis S. Cholesterol determinations in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882.
15. Kostner GM, Laggner P, Chemical and physical properties of lipoprotein. In; Fruchard JC, Shepherd J (eds). Human Plasma Lipoproteins. New York, De Gruyter, 1989; 23-54.
16. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 1946; 58:207-12.
17. Duguid JB. Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J Pathol Bacteriol 1948; 60: 57-61.
18. Smith EB. Fibrin depositin and fibrin degradation pruducts in atherosclerotic plaques. Thromb Res 1994; 75: 329-35.
19. Qizilbash N. Fibrinogen and cerebrovascular disease.Eur Heart J 1995 ;16 (suppl A) :42- 46.
20. Mannucci P.M. Recent progress in the pathophysiology of fibrinogen. Eur Heart J 1995;16 (suppl A):25-30.
21. Meade T.W. Fibrinogen in ischaemic heart disease. Eur Heart J 1995 ;16 (suppl A):31-35.
22. Smith E.B. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16 (suppl A):11-15.
23. Becker R.C et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-q -wave myocarial infarction(TIMI IIIB Trial). Am J Cardiol 1996;78:142-147.
24. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96 (12): 4204-10 .
25. Kesmarky G, Toth K, Habon L, Vajda G, Juricskay I. Hemorheologic parameters in coronary artery disease. Orv Hetil 1998; 139 (24):1465-
8.
26. Behar S. Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention. Blood Coagul Fibrinolysis 1999 ;10 Suppl 1:S41-3.
27. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997 ; 54 Suppl 3: 32-40.

Thank you for copying data from http://www.arastirmax.com